HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including obesity Total deal value of up to $2.3 billion, including upfront, milestone payments and tiered royalties based on net sales SEOUL, South...
Hence then, the article about hanmi pharm signs exclusive licensing deal with genentech for novel obesity therapy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy )
Also on site :
- Doctor who reportedly wrote a paper on violent teens killed in alleged plot involving her daughter and friends
- Katie Miller throws Karoline Leavitt a party with White House lectern cake as speculation continues over replacement
- Las vacunas contra el cáncer podrían transformar el tratamiento y la prevención, pero la desinformación amenaza su potencial